Sanofi Completes Dynavax Acquisition

Sanofi Completes Dynavax Acquisition

Sanofi purchasing Dynavax for 2.2 billion, immediately adds a unique HepatitisB vaccine for adults, Heplisav-B to Sanofi’s currently robust vaccine portfolio, Sanofi is an important vaccine manufacturer partner for PracticeWell’s Physician Buying Group.  Currently PracticeWell member practices have access to discounts for 3 different hepatitisB vaccine brands, Heplisav-B, Merck’s Recombivax-HB as well as GSK’s Engerix-B.  Heplisav-B is unique being the only 2 dose hepatitis b vaccine available in the United States.  Adult patients may complete the hepatitis b immunization series in a month rather than 6 months with the other available options.  In addition to these single entity hepatitis b vaccines, there are combination vaccines that include hepatitis B namely Sanofi & Merck’s collaborative  Vaxelis and GKS’s  Pediarix for infants, and GSK’s Twinrix for adults.

PracticeWell’s PBG offers a robust line of vaccine contracts that covers not only all pediatric and adult vaccines available in the U.S., PracticeWell’s PBG contracts also can assist immunization providers with discounts on travel Vaccines.  Valneva’s IXIARO, Bavarian Nordic’s Vimkuya, Rabavert, Vivotif, Jynneos, and Vaxchora then Sanofi’s YF-Vax, Typhim Vi and Imovax.

Combining these vaccine contracts with decades of experience supporting and advocating for their Pediatric, Family Practice, Internal Medicine, OBGYN members and more, the team at PracticeWell delivers the excellence physicians and their staff deserve.

Join PracticeWell today for free and see how happy you can be!

‍